Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection (AMPLIFY)
7 de julho de 2026 atualizado por: Solenic Medical, Inc.
Acute Management of PJI With Local Implant Retention and Antibiotics Using the Sola2 AMF Knee System: A Multicenter Double-blind Clinical Trial.
The goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection.
The main questions this study aims to answer are:
- Whether adding the Sola2 AMF Knee System improves knee function and quality of life at 6 months.
- Whether adding the Sola2 AMF Knee System to surgery and antibiotic treatment affects the need for additional infection-related surgery.
- Whether the Sola2 AMF Knee System can be used safely, based on device-related adverse events through 12 months.
This study has two stages. In Stage 1, participants will be enrolled into sequential sentinel groups at increasing AMF temperature levels. All sentinel participants will receive active Sola2 AMF treatment. A safety review will occur after each sentinel group before proceeding to the next group. In Stage 2, researchers will compare participants who receive active Sola2 AMF treatment to participants who receive sham AMF treatment. All participants will receive surgery called debridement, antibiotics, and implant retention (DAIR), and antibiotic treatment for knee implant infection.
Participants will:
- Have DAIR surgery for knee implant infection;
- Receive pathogen-appropriate antibiotic treatment from the study doctor;
- If enrolled in Stage 1, receive active Sola2 AMF treatment at the designated sentinel temperature level;
- If enrolled in Stage 2, receive either active Sola2 AMF treatment or sham AMF treatment, depending on randomization assignment; and
- Complete follow-up visits and assessments for safety, infection status, pain, knee function, x-rays, laboratory tests, and other study-related outcomes.
Visão geral do estudo
Status
Ainda não está recrutando
Condições
Descrição detalhada
The AMPLIFY trial is a prospective, multicenter, staged clinical investigation of the investigational Sola2 AMF Knee System in adults with confirmed knee periprosthetic joint infection (PJI) who will undergo debridement, antibiotics, and implant retention (DAIR) surgery and pathogen-appropriate antibiotic therapy.
The study is conducted under a single Investigational Device Exemption and includes two stages. Stage 1 is an open-label sentinel stage using sequential AMF temperature escalation. Sentinel participants receive active Sola2 AMF treatment, with safety review after each sentinel group before progression to the next planned temperature level or to the randomized stage. Stage 2 is a randomized, double-blind, sham-controlled stage in which participants are assigned to active Sola2 AMF treatment or sham AMF treatment.
The Sola2 AMF Knee System is an external, non-contacting investigational device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces. The AMF or sham treatment is administered in the operating room in conjunction with the planned DAIR procedure. All participants receive DAIR and pathogen-appropriate antibiotic therapy as part of their clinical care.
Safety oversight includes medical monitoring, independent Data Safety Monitoring Board review, and independent Clinical Events Committee adjudication as specified in the protocol.
Tipo de estudo
Intervencional
Inscrição (Estimado)
165
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Vice President Clinical Operations
- Número de telefone: 711 U.S.: 877-765-2612
- E-mail: denise.stamos@solenic.com
Estude backup de contato
- Nome: Chief Medical Officer
- Número de telefone: 703 U.S.: 877-765-3612
- E-mail: david.greenberg@solenic.com
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria
Eligible participants must meet all of the following criteria:
- Adult male or female participant aged ≥ 22 years at the time of surgery.
- PJI diagnosis of "infected" knee per the 2018 MSIS Definition of Periprosthetic Hip and Knee Infection.
- Patient presents with PJI symptoms lasting for ≤ 45 days.
- Well-fixed and functioning prosthesis during clinical exam at screening.
- Patient to be treated with DAIR, polyethylene spacer exchange and pathogen- appropriate antibiotic therapy.
- Implanted knee prosthesis must appear on the "AMPLIFY Implant List".
- All implanted knee prosthesis components must have a legible device identification label (implant sticker) available in the medical record.
- Able to comprehend and comply with postoperative instructions and willing to return for follow-up visits for the duration of the study.
- Consent to participate in study and sign the Informed Consent Form (ICF).
Exclusion Criteria
Participants meeting any of the following criteria will be excluded:
- Implanted knee prosthesis not appearing on the "AMPLIFY Implant List".
- Implanted knee prosthesis has any femoral and/or tibial augments, sleeves, cones, or modified/extended stems.
- Un-resurfaced patella.
- Metal-backed patellar components.
- Patients not indicated for a DAIR procedure pre-operatively.
- Patients undergoing bilateral DAIR procedures during the same surgical session.
- Pre-operative determination that the surgical wound cannot be closed primarily and requires a wound vac as a method of wound closure (e.g., open wound managed for secondary intention healing or delayed primary closure); Use of closed-incision negative pressure therapy over a primarily closed incision is permitted.
- Previous DAIR procedure(s) performed on the affected knee joint within the last two years.
- Patients presenting with PJI symptoms lasting for >45 days.
- Patients on antibiotic therapy for an infection other than PJI of the knee.
- Body Mass Index (BMI) ≥ 45.
- Patients currently on bone-marrow suppressive chemotherapy for malignancy.
- Patients currently with active neutropenia.
- Presence of metallic implant(s), other than the femoral and tibial components, within the Sola2 treatment zone (+/- 20 centimeters from the knee joint line) including intramedullary nails, hip prosthesis femoral stem, or fracture fixation hardware.
- Patients with an upper-thigh circumference greater than 70 centimeters (cm) (28 inches (in), measured approximately 15 cm (6 in) proximal to the superior pole of the patella.
- Patients with implanted or nonremovable cardiac pacemakers, defibrillators or cardioverters, insulin pumps, nerve stimulators, or any other indwelling infusion pump.
- Patients who are pregnant or nursing.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1: Stage 1 Sentinel Group A: Active Sola 2 AMF Treatment 55C
Participants in the first open-label sentinel group receive active Sola2 AMF treatment at the planned 55°C AMF temperature level.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
Safety data are reviewed before progression to the next sentinel group.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
Experimental: Arm 2: Stage 1 Sentinel Group B: Active Sola 2 AMF Treatment 60°C
Participants in the second open-label sentinel group receive active Sola2 AMF treatment at the planned 60°C AMF temperature level.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
Enrollment in this group occurs only after safety review supports progression from Sentinel Group A.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
Experimental: Arm 3: Stage 1 Sentinel Group C: Active Sola 2 AMF Treatment 65°C
Participants in the third open-label sentinel group receive active Sola2 AMF treatment at the planned 65°C AMF temperature level.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
Enrollment in this group occurs only after safety review supports progression from Sentinel Group B.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
Experimental: Arm 4: Stage 2 Randomized Active AMF Treatment
Participants randomized to the active treatment arm receive active Sola2 AMF treatment in conjunction with DAIR and pathogen-appropriate antibiotic therapy.
Participants receive two active AMF treatments in the operating room, one before DAIR and one after DAIR and wound closure/bandaging.
|
Active alternating magnetic field treatment is delivered using the investigational Sola2 AMF Knee System.
The system is an external, non-contacting device that generates alternating magnetic fields intended to produce controlled heating at metallic knee implant surfaces.
Treatment is administered in the operating room in conjunction with DAIR.
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
|
|
Comparador Falso: Arm 5: Stage 2 Randomized Sham AMF Treatment
Participants randomized to the sham treatment arm receive sham AMF treatment in conjunction with DAIR and pathogen-appropriate antibiotic therapy.
Participants undergo the same treatment timing and device-use steps as the active treatment arm, but active AMF energy is not delivered.
|
Debridement, antibiotics, and implant retention is the planned surgical treatment for participants with knee prosthetic joint infection participants.
In this study, all participants undergo DAIR, including polyethylene spacer exchange, and receive pathogen-appropriate antibiotic therapy as part of standard clinical care.
Sham alternating magnetic field treatment is delivered during the randomized stage using the Sola2 AMF Knee System workflow.
The sham treatment uses the same treatment timing and device-use steps as active treatment, without delivery of active alternating magnetic field energy
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement
Prazo: Baseline to 6 months
|
Change from baseline to 6 months in the Knee Injury and Osteoarthritis Outcome Score for Joint Replacement.
The score is reported using the validated 0 to 100 interval scoring method, with higher scores indicating better knee health.
|
Baseline to 6 months
|
|
Incidence of Infection-Related Surgical Reintervention
Prazo: From the index DAIR procedure through the primary efficacy analysis, triggered when 24 adjudicated events have occurred and at least 100 participants have completed 12-month follow-up
|
Number and percentage of participants with a qualifying infection-related surgical reintervention event, as adjudicated by an independent Clinical Events Committee.
Qualifying events include surgical reintervention due to relapse or surgical reintervention for ongoing infection, as defined in the protocol.
Only the first adjudicated qualifying surgical reintervention event per participant contributes to the primary endpoint analysis.
|
From the index DAIR procedure through the primary efficacy analysis, triggered when 24 adjudicated events have occurred and at least 100 participants have completed 12-month follow-up
|
|
Incidence of AMF Study Device-Related Adverse Events
Prazo: Through 12 months post-procedure
|
Number and percentage of participants with one or more adverse events determined to be related to the AMF study device.
Potential primary safety endpoint events are independently adjudicated by the Clinical Events Committee according to the CEC charter.
|
Through 12 months post-procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence, Severity, and Relatedness of Adverse Events and Serious Adverse Events
Prazo: Through 12 months post-procedure
|
Between-arm comparison of the incidence, severity, and relatedness of adverse events and serious adverse events.
|
Through 12 months post-procedure
|
|
Time to Resolution and Duration of PJI-Related Signs and Symptoms
Prazo: Through 12 months post-procedure
|
Between-arm comparison of the time to resolution and duration of PJI-related signs and symptoms, such as pain, drainage, erythema, and edema.
|
Through 12 months post-procedure
|
|
Proportion of Participants With Resolution or Marked Improvement of Infection-Related Symptoms
Prazo: Through 12 months post-procedure
|
Between-arm comparison of the proportion of participants with resolution or marked improvement of infection-related symptoms at scheduled follow-up visits.
|
Through 12 months post-procedure
|
|
Change From Baseline in Numeric Rating Scale Pain Score
Prazo: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline in participant-reported pain using the Numeric Rating Scale at scheduled follow-up visits.
Scores range from 0 to 10, with higher scores indicating greater pain.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement at Follow-Up Visits Over Time
Prazo: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline in Knee Injury and Osteoarthritis Outcome Score for Joint Replacement at scheduled follow-up visits other than the 6-month primary endpoint.
Scores are reported using the validated 0 to 100 interval scoring method, with higher scores indicating better knee health.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System Patient-Reported Health Status
Prazo: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline in Patient-Reported Outcomes Measurement Information System patient-reported health status at scheduled follow-up visits.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline and Time to Normalization of C-Reactive Protein
Prazo: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline and time to normalization of C-reactive protein among participants with elevated C-reactive protein at enrollment.
Normalization is defined according to the reference range of the performing laboratory.
|
Baseline through 12 months post-procedure
|
|
Change From Baseline and Time to Normalization of Erythrocyte Sedimentation Rate
Prazo: Baseline through 12 months post-procedure
|
Between-arm comparison of change from baseline and time to normalization of erythrocyte sedimentation rate among participants with elevated erythrocyte sedimentation rate at enrollment.
Normalization is defined according to the reference range of the performing laboratory.
|
Baseline through 12 months post-procedure
|
|
Proportion of Participants Achieving Biomarker Normalization
Prazo: Through 12 months post-procedure
|
Proportion of Participants Achieving Biomarker Normalization
|
Through 12 months post-procedure
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Investigadores
- Investigador principal: Adolph V. Lombardi, MD, Mount Carmel New Albany Surgical Hospital (JIS Orthopedics)
- Investigador principal: Peter K Sculco, MD, Hospital of Special Surgery (New York)
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
31 de julho de 2026
Conclusão Primária (Estimado)
1 de agosto de 2028
Conclusão do estudo (Estimado)
1 de agosto de 2029
Datas de inscrição no estudo
Enviado pela primeira vez
7 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
7 de julho de 2026
Primeira postagem (Real)
14 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
14 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
7 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SOL-200-2025
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Sim
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .